A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Trial Details

NCT ID

NCT06805825

Phase

PHASE1

Sponsor

Novelty Nobility, Inc.

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Locations (sample)

• Ann Arbor, Michigan, United States|42.27756,-83.74088
• Cleveland, Ohio, United States|41.4995,-81.69541
• Portland, Oregon, United States|45.52345,-122.67621
• Houston, Texas, United States|29.76328,-95.36327
• Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

• Subjects must meet the following criteria to be eligible for enrollment into the study:
• Histologically or cytologically confirmed locally advanced, metastatic, and/or unresectable GIST, SCLC, ACC, uveal melanoma, NET ChRCC or ccRCC.
• Subjects must have received the following treatment:
• Part A (Dose Escalation):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.